License Funding and Other Agreements	6 Months Ended
Jun. 30, 2022
License Funding And Other Agreements [Abstract]
License, Funding and Other Agreements	. License, Funding and Other Agreements National Institute of Health In May 2019, the Company was awarded a 5-year grant for up to $1.5 million from the National Institutes of Health (the NIH) to study RTB101 and the regulation of antiviral immunity in the elderly. The Company is entitled to use the award solely to conduct the research. The Company is solely responsible for commencing and conducting the research and will furnish periodic progress updates to the NIH throughout the term of the award. After completing the research, the Company must provide the NIH with a formal report describing the work performed and the results of the research. For funds received under the NIH funding agreement, the Company recognizes a reduction in research and development expenses in an amount equal to the qualifying expenses incurred in each period up to the amount funded by the NIH. Qualifying expenses incurred by the Company in advance of funding by the NIH are recorded in the consolidated balance sheets as other current assets. For the six months ended June 30, 2022, no qualifying expenses have been incurred and nothing has been funded by the NIH. On a cumulative basis as of June 30, 2022, $1.3 million has been incurred and $1.3 million has been funded by the NIH.

License Funding and Other Agreements

6 Months Ended

Jun. 30, 2022

License Funding And Other Agreements [Abstract]

. License, Funding and Other Agreements

National Institute of Health

In May 2019, the Company was awarded a 5-year grant for up to $1.5 million from the National Institutes of Health (the NIH) to study RTB101 and the regulation of antiviral immunity in the elderly. The Company is entitled to use the award solely to conduct the research. The Company is solely responsible for commencing and conducting the research and will furnish periodic progress updates to the NIH throughout the term of the award. After completing the research, the Company must provide the NIH with a formal report describing the work performed and the results of the research.

For funds received under the NIH funding agreement, the Company recognizes a reduction in research and development expenses in an amount equal to the qualifying expenses incurred in each period up to the amount funded by the NIH. Qualifying expenses incurred by the Company in advance of funding by the NIH are recorded in the consolidated

balance sheets as other current assets. For the six months ended June 30, 2022, no qualifying expenses have been incurred and nothing has been funded by the NIH. On a cumulative basis as of June 30, 2022, $1.3 million has been incurred and $1.3 million has been funded by the NIH.